Osimertinib-13C,d3

Modify Date: 2024-01-02 17:14:25

Osimertinib-13C,d3 structure	Common Name	Osimertinib-13C,d3
	CAS Number	2254100-49-5	Molecular Weight	503.62
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₇₁₃CH₃₀D₃N₇O₂	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Osimertinib-13C,d3

Osimertinib-13C,d3 is the deuterium and 13C labeled Osimertinib. Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively.

Name	Osimertinib-13C,d3

Description	Osimertinib-13C,d3 is the deuterium and 13C labeled Osimertinib. Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively.
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.;Hirano T, et al. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third

Molecular Formula	C₂₇₁₃CH₃₀D₃N₇O₂
Molecular Weight	503.62

Osimertinib-13C,d3

Use of Osimertinib-13C,d3

Names

Osimertinib-13C,d3 Biological Activity

Chemical & Physical Properties